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Abstract
All studies using human serotype 5 Adenovirus (Ad) vectors must address two major obstacles: safety and the presence of
pre-existing neutralizing antibodies. Helper-Dependent (HD) Ads have been proposed as alternative vectors for gene
therapy and vaccine development because they have an improved safety profile. To evaluate the potential of HD-Ad
vaccines, we compared replication-competent (RC), first-generation (FG) and HD vectors for their ability to induce immune
responses in mice. We show that RC-Ad5 and HD-Ad5 vectors generate stronger immune responses than FG-Ad5 vectors.
HD-Ad5 vectors gave lower side effects than RC or FG-Ad, producing lower levels of tissue damage and anti-Ad T cell
responses. Also, HD vectors have the benefit of being packaged by all subgroup C serotype helper viruses. We found that
HD serotypes 1, 2, 5, and 6 induce anti-HIV responses equivalently. By using these HD serotypes in heterologous succession
we showed that HD vectors can be used to significantly boost anti-HIV immune responses in mice and in FG-Ad5-immune
macaques. Since HD vectors have been show to have an increased safety profile, do not possess any Ad genes, can be
packaged by multiple serotype helper viruses, and elicit strong anti-HIV immune responses, they warrant further
investigation as alternatives to FG vectors as gene-based vaccines.
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Introduction
A multitude of viral and non-viral vectors are being developed
as vaccines for HIV-1. Adenoviral (Ad) vectors are arguably one of
the most potent gene delivery and vaccine vectors available
[1,2,3,4,5,6]. The vast majority of gene therapy and vaccine
studies have been performed using human serotype 5 Ad (Ad5).
While Ad vectors are robust gene delivery vehicles, they are also
very immunogenic [7].
Innate and adaptive immune responses induced by first-
generation adenovirus (FG-Ad) present several obstacles. First,
innate immune responses induced by intravenous injection of FG-
Ad results in the release of massive amounts inflammatory
cytokines, such as IL-6 and TNF-a, within 3 to 24 hours [8,9].
The events produced by intravenous administration of large doses
can also lead to lethal events [10,11]. Second, most work with Ad
vectors utilizes FG-Ad vectors that are replication-defective due to
a deletion of the E1 gene (Fig. 1B). While they are replication-
defective, these vectors still carry most of the other Ad genes.
These Ad genes can be expressed in transduced cells and be
presented by MHC I and MHC II molecules to immune effector
cells. Because of this, cytotoxic T lymphocytes (CTLs) can
recognize Ad proteins in transduced cells and eliminate these
cells within two to three weeks after vector administration [12,13].
Finally, neutralizing antibodies are also a significant obstacle for
the use of Ad5 viral vectored vaccines. As much as 27.3 to 50% of
humans have pre-existing neutralizing antibodies against Ad5
[14]. In addition, antibodies are generated with each administra-
tion of Ad vector. These neutralizing antibodies can bind,
inactivate and attenuate subsequent gene delivery by these viral
vectors (10).
FG-Ads were created as a safer vector platform with increased
transgene capacity than replication-competent Ad (RC-Ad)
vectors. Helper-dependent Ad (HD-Ad) vectors were produced
to further increase the safety and cloning capacity of Ad vectors. In
HD-Ad vectors, all viral genes are deleted eliminating expression
of potentially toxic and immunogenic viral proteins in transduced
cells (Fig. 1C). For this reason, HD-Ads generate markedly
reduced immune responses against themselves and their transgene
proteins [15,16,17,18]. This reduced immunogenicity allows for
transgene expression in mice and in baboons in some cases over
years [10,19,20,21,22]. This also allows HD-Ad vectors to produce
significantly lower liver damage after i.v. injection than FG-Ad
vectors [23]. For these reasons, HD-Ad vectors are well recognized
in gene therapy applications to have improved safety. More
recently HD-Ad has been explored as a platform to generate
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immune responses against transgene products like b-galactosidase
[24]. In this case, HD-Ad vectors generated stronger T cell and
antibody responses than FG-Ad in mice suggesting they may have
utility as vaccine vectors.
The HD-Ad system is also particularly well suited to serotype
switching, since adenoviruses in the same subgroup can generally
cross-package each other’s genomes. For example, an HD-Ad vector
bearing a packaging signal and ITRs from subgroup C Ad5 can be
cross-packaged by subgroup C Ad2 [21,25]. This allows one to
evade neutralizing antibodies by ‘‘serotype switching’’ the vector
with different capsid antigens. For example, mice immunized with
Ad2 serotype vectors generate potent neutralizing antibodies against
Ad2 that drastically reduce transgene expression if Ad2 is used again
[25]. However, if an Ad2 vector is used for first injection and an Ad5
vector is used for a second injection, there is little reduction in
transduction because the Ad2-specific antibodies do not overtly
neutralize the different Ad5 serotype [25]. Similarly, in baboons,
serotype switching between Ad2 and Ad5 vectors allowed repeat
administration in the face of neutralizing antibodies generated by the
first vector [21,26]. This approach has been applied more recently
for FG-Ad HIV vaccines and has demonstrated the ability to
markedly enhance vaccine responses [27,28,29].
Given their lower immunogenicity, increased safety, and recent
problems related to vector-specific immune responses against Ad
vaccines, this manuscript explores the utility of HD-Ad vectors as
vaccines against HIV-1. In this work, we first compared the in vivo
expression and vector-specific and transgene-specific immune
responses generated by replication-competent Ad (RC-Ad), FG-
Ad, and HD-Ad, all expressing the same transgene. We then
compared the ability of HD-Ad and FG-Ad to drive immune
responses against the HIV-1 envelope antigen. We also tested the
utility of serotype-switching one Ad5 HD-Ad vector with subgroup
C Ad1, Ad2, and Ad6 in mice and in rhesus macaques. This study
is the first example of direct comparison of in vivo gene delivery by
imaging and vector and transgene-specific immune responses
driven by RC-Ad, FG-Ad, and HD-Ad vaccines. This is also the
first study to investigate HD-Ad vectors and multiple serotype-
switching for use as a HIV-1 vaccine in mouse and non-human
primate models.
Materials and Methods
Adenoviruses
First generation replication defective (E1/E3 deleted) Ad5
vectors expressing the green-fluorescent protein-luciferase fusion
protein GFPLuc and expressing HIV-1 Env gp140 from the
subtype B strain JRFL were produced by the Ad-Easy system in
293A cells. Replication-competent Ad5 expressing GFPLuc was
generated by insertion of the CMV-GFPLuc cassette between E1A
and B as described in [30]. HD-Ad viruses expressing GFPLuc
and Env were produced as previously described [31]. Briefly, the
CMV-transgene-SV40 poly A cassettes from the FG-Ad vectors
were PCR amplified, cloned, sequenced, and ligated into the Asc I
site in the HD-Ad vector pD28-E4 (Fig. 1) [32]. Each HD-Ad
plasmid backbone was cut with Pme I and 10 mg of the liberated
viral genome was transfected into a 60-mm dish of 116 cells
expressing Cre recombinase [31]. One day after transfection, the
transfected 116 cells were infected with the E1-deleted serotype 5
(Ad5) helper virus AdNG163 [10]. The packaging signal of
AdNG163 is ‘‘floxed’’ or flanked by loxP sites for deletion during
virus production in Cre-expressing cells. 48 hours later, crude
lysates from this transfection/infection were amplified by serial
coinfections of the crude lysate from the previous passage and
AdNG163. Large-scale HD-Ad were produced by infection of
3 liters of 116 cells as previously described [31] and routinely
produces HD-Ad preps with E1-E3-deleted helper virus contam-
ination below 0.02% [31]. FG and HD-Ad virions were purified
by CsCl banding and concentrations were determined by OD260
and real-time PCR. HD-Ad1, 2, and 6 vectors were also generated
by infection with HD-Ad1, 2, or 6 floxed helper viruses
Ad1LC8cCEVS-1, Ad2LC8cCARP [25], and Ad6LC8cCEVS-
1, respectively. Ad1LC8cCEVS-1 and Ad6LC8cCEVS-1 were
kindly provided by Carole Evelegh and Frank L. Graham
(McMaster University).
Animals
All animal experiments were carried out according to the
provisions of the Animal Welfare Act, PHS Animal Welfare
Policy, and the principles of the NIH Guide for the Care and Use
of Laboratory Animals, and the policies and procedures of Mayo
Clinic and University of Texas MD Anderson Cancer Center.
Mice were purchased from Harlan Sprague Dawley Laboratories
(Harlan, Indianapolis, IN) and maintained at Mayo Clinic. Eight
adult male rhesus macaques (Macaca mulatta) of Indian origin
between the ages of 8–17 years were obtained from and
maintained in the specific pathogen-free breeding colony at the
Michael Keeling Center for comparative medicine and research of
The University of Texas MD Anderson Cancer Center, Bastrop
TX. The animals were anesthetized during procedures to
minimize discomfort.
Mouse Immunizations
Mice were immunized intramuscularly (i.m.) and intravenously
(i.v.). Mice immunized i.m. mice received 161010 vp/mouse in
Figure 1. Schematic representation of adenovirus genome
organization for replication-competent (A), First-Generation
(B), and Helper-Dependent (C) viruses.
doi:10.1371/journal.pone.0005059.g001
Adenoviral Vaccines
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50 ml. For immunization, 25 ml were injected into both quadri-
ceps. Mice immunized i.v. received 161010 vp/mouse in 100 ml
by tail vein injection. For serotype switching experiments, mice
were boosted at 4, 9 and 15 wks after immunization. Groups of
mice were immunized with homologous or heterologous HD-Env.
Splenocytes and sera were harvested 4 wks post-immunization or
at the final time-point for serotype switching and time-dependent
studies.
Luciferase Imaging of Mice
Molecular light imaging of luciferase in vivo was accomplished
using a Lumazone imaging system (Roper Scientific). At 1 and 7
days post- injection, mice were anesthetized with Isoflurane,
injected i.p. with d-luciferin at a concentration of 20 mg/ml in
PBS in a volume of 200 ml and the mice were immediately placed
into the Lumazone Imager and images were captured. All images
were taken with a 10 minute exposure and 262 binning using no
filters and no photo-multiplication. Data analysis was performed
on each image using background subtracted mean intensities
detected by the Lumazone Imaging Software at each time point
and graphed using Prism Graphing Software.
Enzyme Linked Immunosorbent Assay (ELISA)
To measure humoral immune responses to transgenes ELISAs
were performed on mouse sera as previously described [33].
Briefly, Immulon 4 HBX plates (Thermo, Milford, MA) were
coated with 100 ml of HIV-1 envelope (Env) protein, SF162 gp120
(NIH AIDS Reagent and Repository) or FireFly luciferase (Roche,
Switzerland) at 1 mg/ml in PBS for 2 hours at room temperature
(RT). The plates were blocked for 1 h with BSA at 2 mg/ml for
1 hour. Sera were diluted 1:50 in PBS with BSA (1 mg/ml) and
added to the plate for 1 h at RT. The plates were washed with 5
times PBS and 100 ml of Goat anti-mouse HRP conjugated
antibody (Pierce, Rockford, IL) diluted 1:2000 in PBS with BSA
(1 mg/ml) was added to the plate for 1 h at RT. The plates were
washed 5 times with PBS and 100 ml of 1 Step Ultra TMB-ELISA
substrate (Pierce, Rockford, IL) was added for 1 h at RT. The
reaction was stopped with 50 ml of 2 M sulfuric acid and analyzed
at 450 nm using a Beckman Coulter DTX 880 Multimode
Detector.
Enzyme-Linked Immunospot (ELISpot) assay
To measure cellular responses to GFP and Env, splenocytes
were incubated in the presence of peptides at a concentration of
5 mg/ml. GFP CTL responses were determined using the peptide
HYLSTQSAL. The JRFL envelope CTL responses were
determined using the HIV-1, subtype B, strain MN peptide
RKRIHIGPGRAFYTT [34]. Anti-Ad5 cellular responses were
determined using naı̈ve splenocytes that were infected with wild-
type Ad5 as antigen presenting cells (APC). Briefly, splenocytes
were harvested from naı̈ve BALB/c mice. The splenocytes were
infected with wild-type Ad5 virus at 10,000 vp/cell for 1 hr at
37uC. The splenocytes were washed twice with incomplete
DMEM and resuspended in complete DMEM containing 10%
FBS and incubated overnight at 37uC. The infected splenocytes
were then used as APCs in the ELISPOT assay. The spleens from
individual mice were minced and then forced through a 40 mm
Nylon cell strainer (BD Labware, Franklin Lakes, NJ). Single-cell
suspensions of splenocytes were plated in 96-well polyvinylidene
difluoride-backed plates (MultiScreen-IP, Millipore, Billerica, MA)
coated with 50 ml of anti-mouse IFN-c mAb AN18 (5 mg/ml;
Mabtech, Stockholm, Sweden) overnight at 4uC. The plates were
blocked with Hepes buffered complete RPMI medium at 37uC for
2 hr. Equal volumes (50 ml) of each peptide pool and splenocytes
(107 cells/ml) were added to the wells in duplicate. Plates were
incubated overnight (14 to 16 hr) at 37uC with 5% CO2. After the
plates were washed 6 times with PBS, 50 ml of 1:1000-diluted
biotinylated anti-mouse IFN-c mAb (Mabtech, Stockholm,
Sweden) was added to each well. Plates were incubated at RT
for 2 hr and then washed 3 times with PBS. Fifty microliters of
streptavidin-alkaline phosphatase conjugate (1:1000 dilution;
Mabtech, Stockholm, Sweden) were added to each well. After
incubation at RT for 1 hr, the plates were washed 5 times with
PBST. Finally, 100 ml of BCIP/NBT (Plus) alkaline phosphatase
substrate (Moss, Pasadena, MD) were added to each well. The
plates were incubated at RT for 10 min. After washing with water,
plates were air-dried. Spots were counted using an automated
ELISpot plate reader (Immunospot counting system, CTL
Analyzers, Cleveland, OH) and expressed as spot-forming cells
(SFC) per 106 splenocytes.
Tetramer Staining
Tetramers displaying the MHCI CTL epitope IGPGRAFYTT
were obtained from the NIAID MHC Tetramer Core Facility.
Mouse whole blood was collected in microtainer tubes containing
K2EDTA (Becton Dickinson, Franklin Lakes, NJ). The RBCs were
lysed using ACK Lysis buffer and washed twice with DPBS.
Following lysis, 0.2 mg PE-labeled Dd/P18 tetramer and FITC-
labeled anti-mouse CD8a mAb (Ly-2, BD Pharmingen, Franklin
Lakes, NJ) were used to stain P18-specific CD8+ T cells. The cells
were washed in PBS containing 1% FBS and fixed in 0.5 ml PBS
containing 1.5% paraformaldehyde. Samples were analyzed by
two-color flow cytometry on a FACSCalibur (BD Biosciences,
Mountain View, CA). Gated CD8+ T lymphocytes were examined
for staining with the Dd/P18 tetramer.
Macaque Immunizations
Eight macaques from a previous study were used in these
experiments. All eight animals received two immunizations of 1011
vp of Ad-EnvPeptide intranasally approximately 9 months prior to
immunization with HD-Ad in this study. Ad-EnvPeptide expresses six
conserved HIV-1 envelope peptides from a FG-Ad5 vector and [33].
These animals also received six synthetic env peptides adjuvanted
with inactivated cholera toxin or with autologous dendritic cells
during their prior immunizations. These synthetic peptides and Ad-
EnvPeptide do not generate antibody-responses against HIV-1
envelope. In this study, these previously FG-Ad5-immunized
macaques were immunized at days 0, 24, and 67 with 1011 vp of
the indicated HD-Ads by i.m. injection. Serum samples were
collected on days 24, 67, and 100 and 1/50 dilutions were analyzed
for antibodies against envelope by ELISA as described above.
Statistical Analyses
Data was evaluated using GraphPad Prism 4 software.
Unpaired, two-tailed TTests and ANOVA with Bonferroni post
test were used to determine statistical significance. P values#0.05
were considered statistically significant.
Results
Comparison of In vivo Transduction by Replication-
competent Ad (RC-Ad), FG-Ad, and HD-Ad Vectors
In gene therapy tests, HD-Ad vectors have been shown to be
less immunogenic, have improved safety, and mediate extended
expression of transgene products relative to FG vectors
[19,20,21,26]. This extended expression is thought to be due to
the complete deletion of all Ad open reading frames
(ORFs)(Fig. 1C) to reduce T cell responses against Ad antigens
Adenoviral Vaccines
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in transduced cells. In contrast, conventional FG-Ad vectors are
deleted for only E1 and sometimes E3 gene products (Fig. 1B).
While this removes E1 and E3 antigens and reduces expression of
other Ad proteins, at least 17 ORFs are still present and some are
expressed and can targeted by CTLs [15,16,17].
In order to determine the overall ability of the vector platforms
to transduce cells in vivo we compared all three platforms, RC, FG
and HD, using the Ad 5 serotype. RC-Ad was used as a positive
control for this experiment since it is thought to produce stronger
immune responses and toxicity due to replication and production
of viral antigens than replication-defective vectors.
RC5, FG5 and HD5 vectors expressing the GFPLuc (GL)
transgene were injected i.m. and i.v. into BALB/c mice and the
overall transgene expression was determined by luciferase imaging
(Fig. 2). Luciferase expression levels after i.m. injection are shown
in figure 2A. At day 1 after i.m. injection, both FG5-GL and HD5-
GL had significantly higher luciferase expression as compared to
RC5-GL (p = ,0.01 and ,0.05, respectively). Although all vectors
had reduced luciferase expression levels at day 7, HD5-GL had
significantly higher levels as compared to FG5-GL (p = ,0.05)
(Fig. 2A). Luciferase expression levels after i.v. injection are shown
in figure 2B. Overall transgene expression was greater than 10-fold
higher in i.v. injected mice as compared to i.m. injected mice. The
most significant difference was seen in the RC5-GL injected mice
where expression levels were more than 300 fold higher than i.m.
expression levels and is most likely due to replication in the liver.
Although reduced expression levels were observed for both FG5-
GL and HD5-GL vectors after i.v. injection as compared to RC5-
GL at day 1, there were no significant differences between the two
replication-defective vectors (Fig. 2B). Expression levels for all
vector platform were markedly reduced by day 7 and there were
no significant differences between all vector platforms (Fig. 2B).
Comparison of Transgene-directed T Cell Responses
In order to determine if any one vector platform was better at
inducing cellular immune responses, mice were immunized i.m.
and i.v. with all three vectors expressing GFPLuc using the Ad5
serotype. The animals were sacrificed at 4 weeks post-immuniza-
tion and their splenocytes were tested for T cell responses against
GFP by ELISPOT (Fig. 3A and B). All vector platforms induced
equivalent T cell responses against the GFPLuc transgene. There
were no statistically significant differences in anti-GFP cellular
immune responses after i.m. immunization with RC, FG or HD
vectors (Fig. 3A). Similarly, i.v. immunization produced equivalent
anti-GFP T cell responses by all vectors as evidenced by ELISPOT
(Fig. 3B). We also compared the ability of FG5-Env and HD5-Env
to induce anti-Env cellular immune responses (Fig. 3E). RC5-Env
was not available for comparison. We found that both FG5 and
HD5 platforms induced anti-Env cellular responses equally and
there were no significant differences (Fig. 3E).
Comparison of Transgene-directed Antibody Responses
Serum was drawn from the GFPLuc-immunized animals 4
weeks after immunization and was tested for antibodies against
luciferase (Fig. 3C and D). Both RC5-GL and HD5-GL induced
significantly higher levels of Anti-luciferase antibodies after i.m.
injection than FG-Ad (p = ,0.01 and ,0.001, repectively)
(Fig. 3C). Luciferase antibodies were approximately 2-fold higher
by the i.v. route for all vectors. Similarly, i.v. injection of RC5-GL
and HD5-GL also produced significantly higher levels of anti-
luciferase antibodies than FG-Ad (p = ,0.01 and ,0.001,
respectively) (Fig. 3D). Interestingly, HD-Ad produced antibody
responses that were equal to or higher than those produced by
RC-Ad by both routes. In contrast, FG-Ad antibody levels were
approximately one half of the levels produced by HD-Ad
consistent with previous studies [24]. These data indicate that
HD-Ad vectors produce antibody levels comparable to replication-
competent Ad and higher than FG-Ad. We also compared the
ability of FG5-Env and HD5-Env to induce anti-Env antibody
responses (Fig. 3F). We found that both FG5 and HD5 platforms
induced anti-Env antibody responses equally well at both 4 wks
and 9 wks post-immunization and there were no significant
differences (Fig. 3F).
Comparison of Vector Safety
In mice, one side effect of Ad administration is liver damage
after i.v. injection. To compare the toxicities of the three vectors,
each was injected i.m. or i.v. into groups of 5 mice and liver
enzyme ALT levels were measured in the blood 48 hours later
(Fig. 4A and B). When ALT levels were tested after i.m. injection,
no increases were observed with any of the vectors consistent with
their sequestration from the blood and the liver (Fig. 4A). As
expected, RC5-GL generated the highest ALT levels after i.v.
injection that were significantly higher than FG5-GL and HD5-
GL (p = ,0.001). In contrast, HD5-GL produced only back-
ground levels of ALT consistent with previous results [23].
Figure 2. Luciferase imaging. In vivo transduction and expression produced by RC-Ad, FG-Ad, and HD-Ad expressing GFPLuc after i.v. (A) and i.m.
(B) immunization. Groups of 5 mice were administered 1010 vp of the indicated vectors by the indicated routes. The animals were anesthetized,
injected with luciferin, and imaged for luciferase activity at 1 and 7 days after injection. Data is shown for sum luciferase intensity for the muscles in
i.m.-injected mice and for the liver in i.v.-injected mice. Data is the mean of luciferase activity from 5 mice for each group and error bars indicate
standard error. The data were analyzed by one-way ANOVA (* = p,0.05 and ** = p,0.01).
doi:10.1371/journal.pone.0005059.g002
Adenoviral Vaccines
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Although considered safer than RC-Ad, FG5-GL produced liver
damage that was intermediate between RC5-GL and HD5-GL
indicating that the first generation vector is safer than RC-Ad, but
less safe than HD-Ad (Fig. 4B). This is consistent with previous
data showing lower liver damage by HD-Ad than FG-Ad [23].
Comparison of Ad5-directed T Cell Responses
ELISPOTs were also performed against Ad5 using splenocytes
infected with wild-type Ad5 (Fig. 4C and D). Anti-Ad cellular
immune responses were up to five-fold higher after i.m. injection
(Fig. 4C) as compared to i.v. immunization (Fig. 4D). In this case,
both the RC5-GL and FG5-GL vectors generated significantly
higher Anti-Ad5 cellular responses (p = ,0.05) as compared to the
HD-Ad vector indicating that the absence of viral genes in the
vector blunted the level of vector-directed T cell responses. In
contrast Anti-Ad responses were lower by the i.v. route than the
i.m. route. By the i.v. route all vectors produced relatively low
responses and no significant differences with averages of 150 IFN-
c SFCs (Fig. 4D).
Figure 3. Humoral and cellular immune responses. Vector induced humoral and cellular immune responses against the transgene products
were quantitated. Anti-GFP cellular immune responses induced by i.m. (A) and i.v. (B) injection are shown as IFN-c spot forming cells (SFC) as
measured by ELISPOT of splenocytes 4 weeks after immunization. Splenocytes were pulsed with H-2Kd-restricted GFP peptide. Data is the mean from
5 mice for each group and error bars indicate standard error. Anti-luciferase antibody responses in sera from the i.m (C) and i.v. (D) immunized mice
were collected 4 weeks after injection and were assayed by ELISA. Cellular and antibody immune responses against the HIV-1 envelope transgene are
shown were quantitated after i.m. immunization with FG and HD vectors (E and F, respectively). Data is the mean ELISA OD450 from 5 mice for each
group and error bars indicate standard error. The data were analyzed by unpaired two-tailed TTEST (** = p,0.01 and *** = p,0.001).
doi:10.1371/journal.pone.0005059.g003
Adenoviral Vaccines
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Serotype-switching HD-Ad Vectors for HIV Vaccination
To test the utility of HD-Ad for serotype-switching, an HD5
vector expressing the HIV-1 JRFL envelope (Env) was
packaged by Ad1, 2, 5, or 6 helper viruses and the resulting
virions were used for i.m. immunization in mice (Fig. 5). Each
HD-Ad produced similar anti-env antibodies when sera were
assayed 4 weeks later by ELISA (Fig. 5A). When T cells in the
blood were assayed by flow cytometry with env-specific MHC I
tetramers, CD8+/tetramer+ cells were detected in all groups
with HD1-Env and HD2-Env generating two-fold higher
responses than HD5 and HD6 vectors after the first
immunization (Fig. 5B).
To test serotype-switching of one HD-Ad vector backbone,
the HD-Ad vectors were used for prime-boost immunizations.
The groups of 20 mice that were primed with the four HD-Ad
serotypes were each split into two groups of mice and they were
boosted with either homologous HD-Ad or a heterologous HD-
Ad serotype vector also expressing env. Four weeks after
boosting, blood was collected and evaluated for humoral and
cellular immune responses to HIV Env (Fig. 5A and B,
respectively). All heterologous prime-boost regimens induced
higher Anti-Env ELISA titers as compared to homologous
prime-boosted mice (Fig. 5A). All mice boosted with heterolo-
gous HD-Env had significantly higher Anti-Env antibody titers
at all post-boost time points (p = ,0.001) (see Supplementary
Table S1). Cellular responses assessed by MHC I tetramer
staining were also higher in mice immunized with heterologous
prime-boost regimens, as compared to homologous prime-
boosting (Fig. 5B). Because the PBMCs were pooled for
tetramer analysis after the second immunization, statistical
analyses were not performed at that time point. There were no
statistical differences between HD-Ad serotypes after the first
immunization. However, analysis by two-way ANOVA after the
third and fourth immunization showed statistically significant
higher tetramer responses in mice boosted with heterologous
HD-Ad with some p values,0.001 (Supplementary Table S2).
After the fourth immunization, env antibodies declined in all
groups, perhaps due to saturation of the responses or in response
to regulatory cells. Third and fourth round immunization did
not boost T cell responses in either group, however, tetramer
levels remained statistically higher in all of the heterologous
boosted mice after the third immunization and some of the
heterologous boosted mice after the fourth immunization as
compare to the homologous boosted mice (Fig. 5B). At the end
of the study, the animals were sacrificed and their T cell
responses were assayed from splenocytes by ELISPOT (Fig. 6).
Stimulation of the cells with MHC II (Fig. 6A) or MHC I-
restricted peptides (Fig. 6B) generated lower numbers of SFCs
from the mice that were immunized only with one serotype of
HD-Ad. Total SFCs were 2 to 4-fold higher in most of the
groups immunized by serotype-switching with the HD-Ad
vectors (Fig. 6C).
Figure 4. Toxicity and anti-vector cellular immune responses. Toxicity and the induction of anti-vector cellular immune responses were
measured. Liver toxicity is expressed as a measured of ALT expression 48 hours after i.m. (A) and i.v. (B) injection. Anti-adenovirus cellular responses
were measured 4 wks after i.m. (C) and i.v. (D) injections. Naı̈ve BALB/c splenocytes infected with wild-type Ad5 were used as antigen presenting cells
and were co-cultured with splenocyted from immunized mice. Anti-Ad5 cellular responses were measured by ELISPOT. Data represent groups of 5
mice and error bars indicate standard error. The data were analyzed by one-way ANOVA (* = p,0.05 and *** = p,0.001).
doi:10.1371/journal.pone.0005059.g004
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Testing HD-Ad Serotype-switching in FG-Ad5-immune
Macaques
A group of eight macaques from another study were available to
test the HD-Ad vaccines. These macaques had previously been
immunized with various formulations of six conserved HIV-1 env
peptides (see Materials and Methods). Of interest to our work,
these animals had also been immunized twice intranasally with
FG-Ad5-EnvPeptide [33]. Since they had been exposed to Ad5
intranasally, these animals had the potential to mimic a natural
Ad5 respiratory infection. In addition, these peptides generate T
cell responses against HIV-1 envelope, but do not produce
antibody responses against the protein [35,36,37,38,39]. There-
fore, they could be used to evaluate anti-env antibody responses
driven by HD-Ad vectors.
To test this, two groups of 4 macaques were immunized i.m.
with 1011 vp of HD-Ad expressing HIV-1 env JRFL gp140 (HD-
Env). On day 0, group one received HD5-Env and group two
received HD6-Env by the i.m. route. On day 24, group one again
received HD5-Env and group two received HD1-Env. On day 67,
group one received HD5-Env for a third time whereas group two
received HD12-Env. Serum samples were collected on days 24,
67, and 100 and evaluated by ELISA for anti-env antibodies
(Fig. 7). FG-Ad5-immune animals that were immunized three
times with HD5-Env generated only minimal antibody responses.
In contrast, FG-Ad5 immune animals that were immunized with
HD6-Env, HD1-Env, and HD2-Env generated detectable anti-
env antibodies at each immunization with final antibody levels
being 10-fold higher than in the HD-Ad5 group (p,0.01). These
data demonstrate the breadth of a HD-Env vector packaged by
multiple serotype helper viruses to evade pre-existing or vector
induced immune responses.
Discussion
This study was directed at determining if HD-Ad vectors would
have utility as gene-based vaccine platforms. To evaluate both
vaccine potential and vector side effects, we compared HD5-Ad to
replication-defective FG5-Ad and replication-competent RC5-Ad.
These data demonstrate that HD-Ad and RC-Ad both generate
stronger immune responses than FG-Ad. In contrast, FG-Ad and
RC-Ad both generated higher anti-Ad T cell responses and liver
damage indicating that HD-Ad has a better safety profile than
either of these vectors. These data indicate that HD-Ad vaccines
generate strong immune responses against gene-based antigens,
but have reduced side effects. This data is consistent with previous
gene expression and safety work comparing HD-Ad and FG-Ad
for gene therapy applications [10,26]. It is also consistent with
previous work comparing the ability of FG-Ad and HD-Ad
expressing b-galactosidase to generate immune responses [24]. In
this case, HD-Ad vector also generated stronger T cell and
antibody responses than FG-Ad [24].
In light of the HIV-1 human vaccine STEP trial results, HD-Ad
vectors may have the an advantage in not expressing any Ad
antigens from transduced cells. As shown in Figure 1, conventional
E1/E3-deleted FG-Ad vectors still carry 17 potential vector
antigen ORFs whereas HD-Ad has zero. While E1 and E3
deletion renders FG-Ad vectors largely (but not completely)
replication-defective, this still allows Ad proteins to be expressed in
a leaky fashion [13]. It appears that this leaky expression in
transduced cells is what stimulates new T cell responses and recall
T cell responses against the vector which destroy transduced cells.
If Ad-specific T cell responses are involved in increasing HIV-1
acquisition in the STEP trial, then it is possible that an HD-Ad
vector would reduce this side effect. This is suggested by the lower
anti-Ad T cell responses generated by HD-Ad as compared to
both FG-Ad and RC-Ad.
While HD-Ad did have lower anti-Ad T cell responses, they
were not zero. This is likely due to T cell responses due to the
delivery of Ad antigens from the incoming HD-Ad virions. One
approach to mitigate T cell and antibody responses versus Ad due
to protein delivered in the virion would be coating the virus with
polymers like polyethylene glycol (PEG). Indeed, PEGylated HD-
Ad vectors appear as robust as unmodified vectors [23,40]. This
effect of carried protein antigen can also largely be obviated by
using HD-Ad vectors from infrequently observed Ad serotypes and
performing serotype switching [21,25,27,28,29]. Towards this end,
we show that serotype switching of HD-Ad vectors is simple by
using alternate serotype helper-viruses from the same Ad
subgroup. We show that one HD-Ad genome can be packaged
by four different helpers and that each of these generates robust
HIV-directed immune responses. Serotype switching allowed for
multiple rounds of boosting that increased anti-Env immune
responses significantly as compared to homologous boosting. In
general, the anti-Env immune responses plateaued after the third
Figure 5. Anti-env humoral and cellular responses induced by
HD-Ad serotypes. Groups of 20 BALB/c mice were immunized i.m.
with 1010 vp of HD-Ad vectors expressing the HIV-1 JRFL gp140 env. A)
Sera antibodies were assayed by ELISA 4 wks after priming, prior to
boosting and 3 wks after final boosting. B) Tetramer staining was
perfomed 4 4 ks after priming, prior to boosting and 3 wks after final
boosting. The percent CD8+/tetramer+ cells was determined by flow
cytometry. Data is the mean activity from 20 mice for each group for
priming and 10 mice for each group boosted. Error bars indicate
standard error and the data were analyzed by two-way ANOVA
(** = p,0.01 and *** = p,0.001).
doi:10.1371/journal.pone.0005059.g005
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immunization. This may be due to a down regulation of anti-Env
responses by regulatory cells or by saturation of the transgene
product by circulating anti-Env antibodies. While these serotypes
were convenient to test proof of principle as they were existing
vectors, Ad1, 2, and 5 serotypes are not optimal, since pre-existing
immunity in humans range from 27 to 50% for these viruses. In
contrast, pre-existing immunity to Ad6 may be as low as 3% [14],
which may make HD-Ad6 of interest in a DNA prime- HD-Ad6
boost or in combination with HD-Ads produced from less
prevalent serotypes.
In summary, HD-Ad vectors produce immune responses equal
to or better than FG and RC Ad vaccines that carry viral ORFs.
HD-Ad vaccines produce lower side effects and vector-directed T
cell responses likely due to the absence of these viral genes in the
vector. HD-Ad serotype-switching proved effective at generating
stronger immune responses against HIV-1 envelope in both mice
and FG-Ad5-immune macaques. Based on this, HD-Ad vectors
from low seroprevalence adenoviruses may have utility as vaccines
for HIV and other pathogens.
Supporting Information
Table S1
Found at: doi:10.1371/journal.pone.0005059.s001 (0.06 MB
PDF)
Table S2
Found at: doi:10.1371/journal.pone.0005059.s002 (0.08 MB
PDF)
Figure 7. Evaluation of serotype switch in pre-immune
macaques. Pre-immune macaques were immunized with 1011 vp of
homologous or heterologous HD-Ad expressing HIV-1 gp140 Env. The
macaques were boosted with 1011 vp of homologous or heterologous
HD-Ad at days 24 and 67. Sera was collected on days 24, 67 and 100 and
used to measure Anti-Env ELISA antibodies. Data is the mean of 4
macaques per group and error bars indicate standard error. Data was
analyzed by one way ANOVA (* = p,0.05 and ** = p,0.01).
doi:10.1371/journal.pone.0005059.g007
Figure 6. Effects of HD serotype switching on boosting anti-
HIV T-helper and CTL responses. Mice were immunized i.m. with
HD-Ad expressing HIV-1 gp140 Env. The mice were boosted with
homologous or heterologous HD-Ad 3 times before ELISPOT assays
were performed. Splenocytes from immunized mice were isolated and
stimulated with T-helper (Th) epitope peptides (A) or a CTL epitope
peptide (B). The total anti-Env cellular immune responses are also
shown (C). Data is the mean activity from 10 mice for each group. Error
bars indicate standard error and the data were analyzed by unpaired
two-tailed TTEST.
doi:10.1371/journal.pone.0005059.g006
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